vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $13.2M, roughly 1.0× Ares Commercial Real Estate Corp). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -29.2%, a 104.9% gap on every dollar of revenue.
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
ACRE vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $13.7M |
| Net Profit | $-3.9M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | -86.5% |
| Net Margin | -29.2% | 75.7% |
| Revenue YoY | -24.5% | — |
| Net Profit YoY | 63.8% | 179.1% |
| EPS (diluted) | — | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $13.7M | ||
| Q3 25 | $14.1M | $19.1M | ||
| Q2 25 | $12.6M | $8.1M | ||
| Q1 25 | $14.9M | $2.9M | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $16.7M | — | ||
| Q2 24 | $16.8M | — | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $-3.9M | $10.4M | ||
| Q3 25 | $4.7M | $-16.3M | ||
| Q2 25 | $-11.0M | $-15.8M | ||
| Q1 25 | $9.3M | $-13.3M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-5.9M | — | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $-12.3M | — |
| Q4 25 | -29.2% | -86.5% | ||
| Q3 25 | 33.0% | -10.1% | ||
| Q2 25 | -87.8% | -177.7% | ||
| Q1 25 | 64.4% | -472.7% | ||
| Q4 24 | -61.0% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | — |
| Q4 25 | -29.2% | 75.7% | ||
| Q3 25 | 33.0% | -85.4% | ||
| Q2 25 | -87.8% | -196.0% | ||
| Q1 25 | 62.5% | -452.7% | ||
| Q4 24 | -60.9% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $137.5M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $35.3M |
| Total Assets | $1.6B | $154.7M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $137.5M | ||
| Q3 25 | $84.9M | $103.8M | ||
| Q2 25 | $90.0M | $121.6M | ||
| Q1 25 | $125.5M | $89.1M | ||
| Q4 24 | $63.8M | — | ||
| Q3 24 | $68.9M | — | ||
| Q2 24 | $70.6M | — | ||
| Q1 24 | $99.5M | — |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | $35.3M | ||
| Q3 25 | $521.0M | $-8.1M | ||
| Q2 25 | $523.7M | $7.1M | ||
| Q1 25 | $542.1M | $10.7M | ||
| Q4 24 | $540.1M | — | ||
| Q3 24 | $563.8M | — | ||
| Q2 24 | $582.3M | — | ||
| Q1 24 | $601.1M | — |
| Q4 25 | $1.6B | $154.7M | ||
| Q3 25 | $1.4B | $133.7M | ||
| Q2 25 | $1.4B | $133.8M | ||
| Q1 25 | $1.5B | $103.7M | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $-2.0M | ||
| Q3 25 | $3.8M | $-17.5M | ||
| Q2 25 | $4.9M | $-14.5M | ||
| Q1 25 | $8.0M | $29.0M | ||
| Q4 24 | $35.5M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $11.4M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
